Built for Biotech: Clinical Outsourcing That Scales with Innovation

Biotech pipelines are funding driven, milestone sensitive, and inherently changeable. Early data can trigger rapid pivots. Investment cycles create urgency around critical inflection points. Yet many functional service provider (FSP)  approaches are still designed for stability. When volatility hits, those models often strain, or break, under pressure.

The unique pressures Biotech sponsors face in FSP models

Biotech sponsors are operating under a distinct set of constraints that some of the traditional CRO resourcing models were never built to absorb.

Pipeline volatility is a constant. Programmes may pause, accelerate, or reprioritise based on emerging data, often with little warning. Funding and milestone pressure intensify this reality, creating intense urgency around IND submissions, Phase I safety readouts, or Phase II proof of concept milestones tied directly to financing.

At the same time, many Biotech organisations run lean. Limited internal infrastructure, evolving SOPs, and constrained governance bandwidth place additional responsibility on outsourced flexible resourcing models to work first time. Layer onto this the complexity of innovation through novel modalities, bespoke trial designs, and evolving regulatory pathways and the margin for error narrows quickly.

Why traditional FSP models break under Biotech pressure

Many CRO resourcing models operate around a one size fits all model, which often assume stability. They scale headcount, not thinking. They deliver exactly what’s written in scope — even when the scope no longer reflects the sponsor’s reality. In these models, governance often becomes reactive rather than preventative, changes are identified too late and course correction comes after disruption has already occurred.

Biotech doesn’t need more flexibility in theory. It needs adaptability with predictability by design. 

How Fortrea ‘s blended delivery model is built differently: curiosity, flexibility and culture

Fortrea challenges how functional outsourcing is usually delivered. Not by executing harder, but by enabling better decisions earlier. Our blended delivery model is treated as a deliberate operating model — not a resourcing workaround — designed to flex as priorities change, hold under pressure, and remain governable at a portfolio level. Our approach is grounded in three integrated pillars:

1. Relentless curiosity to challenge the status quo: Fortrea teams invest time early to understand how our sponsors truly operate; where risk is quietly building, which assumptions are fragile, and which decisions will matter months from now. Better outcomes don’t come from blind execution, they come from better questions to bring challenge led thinking directly into delivery:
   • Scan early to identify real pressure points before they become constraints
   • Challenge assumptions around resourcing, governance, and ownership
   • Design fit-for-purpose operating models aligned to sponsor reality
   • Monitor signals through continuous insight, not post mortems

2. Built in flexibility enables these models to evolve in line with the sponsor’s needs. Fortrea’s Blended Delivery models are living operating frameworks— not rigid instruction packs — designed to absorb change without sacrificing continuity, accountability, or control. Our models are designed with our Biotech customers and adapted deliberately as their reality shifts, rather than reset reactively.

   As a right-sized CRO we are large enough to scale, structured to adapt, and built so that agility is predictable by default.

3. Culture acts as a delivery accelerator. Culturally integrated teams consistently outperform those that are only functionally aligned1,2. Culture shapes trust, decision making, and the confidence to speak up early when assumptions no longer hold. Our integrated delivery team model deliberately encourages accountability, shared ownership, and constructive challenge — creating stability even as programmes evolve.

“Fortrea’s RADAR framework goes beyond execution—challenging assumptions early and building a flexible operating model that evolves as your pipeline and priorities change. Our passion for working with Biotech comes from the purpose behind the science: bold ideas, lean teams, and a deeply personal commitment to making a difference for patients. That sense of urgency and belief is why we invest ourselves as true collaborators, not just providers.” – Dawn Williams, Executive Director, Clinical FSP Customer Delivery Unit

Charting a steady course in an uncertain clinical development environment

Biotech success isn’t about avoiding change — it’s about designing operating models that expect it. As innovation accelerates and pipelines evolve, outsourcing models must be built to flex without losing control.

Fortrea’s approach to blended delivery  is predictable by default, curious by design, and built to evolve alongside Biotech sponsors — helping you stay on course, even when conditions change. Want to know more about how our team can help accelerate your business, contact us  to set up a call.

References

1. McKinsey & Company. (n.d.). Why managing culture is critical for value creation in M&A. McKinsey & Company.  https://www.mckinsey.com/capabilities/m-and-a/our-insights/why-managing-culture-is-critical-for-value-creation-in-m-and-a   (Last updated February 2025, last accessed April 2026)
2. Bain & Company Maceda, M. (n.d.). Building a consistently excellent culture: Bain’s Manny Maceda.  https://sloanreview.mit.edu/article/building-a-consistently-excellent-culture-bains-manny-maceda/   (Last updated November 2024, last accessed April 2026)